Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib
DOI: https://doi.org/10.2147/JHC.S396231
2023-02-16
Journal of Hepatocellular Carcinoma
Abstract:Zhonghao Jiang, Chaoliu Dai Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China Correspondence: Chaoliu Dai, Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China, Email Liver cancer is highly malignant, has a low sensitivity to chemotherapy, and is associated with poor patient prognosis. The last 3 years have seen the emergence of promising targeted therapies for the treatment of hepatocellular carcinoma (HCC). For over 10 years, before the discovery of lenvatinib, sorafenib was only first-line therapeutic agent available for the treatment of advanced HCC. However, several clinical studies have shown that a considerable proportion liver cancer patients are insensitive to sorafenib. Very few patients actually substantially benefit from treatment with sorafenib, and the overall efficacy of the drug has not been satisfactory; therefore, sorafenib has attracted considerable research attention. This study, which is based on previous studies and reports, reviews the potential mechanisms underlying sorafenib resistance and summarizes combination therapies and potential drugs that can be used to sensitize HCC cells to sorafenib. Keywords: hepatocellular carcinoma, sorafenib, drug resistance, combination therapy, target therapy Hepatocellular carcinoma (HCC) is insidious in nature and has a low early diagnosis rate. Surgical resection, local ablation, and liver transplantation are potential curative treatment options for early-stage HCC. Sorafenib has long been the main targeted drug used for the systemic treatment of advanced liver cancer. It is an oral multi-kinase inhibitor and inhibits intracellular serine/threonine kinases (including Raf-1, wild-type B-Raf, and mutant B-Raf) and receptor tyrosine kinases (RTKs) (including the vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptors β and c-KIT, FMS-like tyrosine kinase 3, and RET), thereby inhibiting tumor proliferation and angiogenesis. 1,2 However, only 35–43% of patients respond to sorafenib, and most of them relapse within 6 months. 3,4 Therefore, elucidating the mechanisms underlying sorafenib resistance (SR) is important for the improvement of survival in HCC patients. Because of the existence of complicated signaling cross-talk within HCC cells, which leads to the development of multiple compensatory mechanisms and alternative pathways, HCC patients respond differentially to sorafenib. Elucidating the mechanisms underlying SR and enhancing drug sensitivity are key strategies for improving the clinical efficacy of sorafenib. Hypoxia is commonly occurs in solid tumors such as HCC. 5 Since the speed of vasculogenesis is not sufficient to meet up with rapid tumor growth, oxygen and nutrient supply is usually limited. Hypoxia inducible factors (HIFs) are the main transcriptional regulators of the adaptive response to hypoxia in HCC cells. 6 Oxygen content is a critical determinant of cellular HIF homeostasis. HIFs contain an oxygen-dependent degradation domain (ODDD) of approximately 200 residues that regulates their degradation. The ODDD contains two oxygen-dependent prolyl hydroxylation sites, both of which can be hydroxylated by prolyl hydroxylases. 7 Under normal oxygen supply conditions (normoxia), hydroxylated HIF1α is recruited by the von Hippel-Lindau ubiquitination complex (VHL) and degraded in a ubiquitination-dependent manner (Figure 1). In addition, HIF1α can degraded through the autophagy pathway. 8 Under hypoxia-induced stress conditions, HIF cannot be hydroxylated or stabilized for the activation the transcription of over 40 genes that facilitate angiogenesis and the shift in cell energy metabolism to anaerobic glycolysis. 9 HIF1α has been identified to be relevant in chemoresistance, tumor aggressiveness, and poor prognosis in HCC patients. 10 Interestingly, HIFs tend to exhibit dual characteristics under sorafenib-induced stress conditions. As a drug with anti-angiogenesis activity, sorafenib has VEGF as one of its main targets. 11 In vivo studies have shown that sorafenib downregulates the synthesis of both HIF1α and VEGF. 12 Of note, VEGF is also a key downstream factor that affects HIF expression. However, long-term treatment with sorafenib paradoxically induces an increase in HIF transcription and translation. 13 This could be because the hypoxia microenvironment, which develops due to the anti-angiogenesis effects of sorafenib, selects for more resistant and invasive HCC clones. 13,14 Figure 1 Mechanism of HIF-dependent sorafenib sensitization. HIFα is hydroxylated by prolyl hydroxylases under normoxia conditions and binds with -Abstract Truncated-
oncology